Covered recipient · General Payments record
KEVIN CASE
Allopathic & Osteopathic Physicians Family Medicine
General Payments · PY2022–2024
$159.00
- Reported across 10 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $144.23 | 9 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| NOVARTIS PHARMACEUTICALS CORPORATION | $36.53 | 2 |
| ABBVIE INC. | $31.90 | 2 |
| Novo Nordisk AS | $31.52 | 2 |
| Otsuka America Pharmaceutical, Inc. | $15.16 | 1 |
| AIMMUNE THERAPEUTICS, INC. | $14.69 | 1 |
| GlaxoSmithKline, LLC. | $14.43 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (9)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $16.58 | 08/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103425131 | CMS |
| ABBVIE INC. | $15.32 | 10/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103425133 | CMS |
| AIMMUNE THERAPEUTICS, INC. | $14.69 | 10/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1147005807 | CMS |
| GlaxoSmithKline, LLC. | $14.43 | 09/26/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116077297 | CMS |
| Novartis Pharmaceuticals Corporation | $17.86 | 10/30/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1086778357 | CMS |
| Novartis Pharmaceuticals Corporation | $18.67 | 11/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1086778371 | CMS |
| Novo Nordisk Inc | $14.20 | 08/14/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096867975 | CMS |
| Novo Nordisk Inc | $17.32 | 10/28/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097489009 | CMS |
| Otsuka America Pharmaceutical, Inc. | $15.16 | 08/29/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1118872280 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2022, 2024
- Source files
- Dataset page · Bulk file · PY2022 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.